强生、雅培和波科在2023年Q2业绩中表现各异。强生以237亿美元的营收位居首位，增长5.8%，其中医疗器械业务贡献了85亿美元，心血管业务成为主要增长点（+23.5%）。然而，骨科和外科业务增长缓慢，分别仅增长0.3%和2.7%。雅培紧随其后，总营收111.4亿美元，增长7.4%，医疗器械业务增长13.4%，主要驱动力来自糖尿病护理、心衰治疗和电生理业务。波科虽然销售额最低（50.6亿美元），但...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.